Go beyond the consensus and become a better stock picker with Earnings Whisper numbers, investor sentiment, and proprietary research and tools to help you capture the Post-Earnings Announcement Drift (PEAD) and outperform the overall stock market. Plus, get the most accurate earnings dates, earnings news, and insights into how stocks react before
and after earnings.
The most anticipated earnings releases for the week beginning September 18, 2026 are
COSTCostco WholesaleBBBlackBerryCBRLCracker Barrel Old Country StoreTHOTHOR IndustriesDRIDarden Restaurants
COSTCostco Wholesaleis confirmed to report Thursday, September 24, after the close.
Costco's Margin Trade-Off Faces Its Next Test as Stock Slides Below Its 200-Day Average
Costco heads into its fiscal fourth-quarter report carrying one of the more interesting tensions in retail right now: sales momentum has been accelerating for four straight quarters, yet the stock has fallen 8.6 percent since the last print while the S&P 500 gained slightly. That divergence is the central puzzle investors need this report to resolve.
Wall Street expects EPS of $6.48 on revenue of $94.78 billion, representing roughly 10 percent growth on both lines. The Earnings Whisper number sits marginally higher at $6.54, suggesting the bar is not dramatically elevated but skews slightly optimistic. Costco does not issue formal guidance, so the real benchmark is the trajectory management laid out last quarter, when net sales growth hit 11.6 percent, the fastest of the past four quarters, powered by record-breaking gasoline volumes and comps ex-gas and FX holding near 6.6 percent. If that pace decelerates meaningfully from Q3 levels, it would be the first crack in an otherwise strengthening demand story.
Innate Pharma S.A. (IPHA) reported a loss of $0.24 per share on for the second quarter ended June 2026. .
Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.
Lennar (LEN) reported earnings of $1.23 per share on revenue of $8.05 billion for the fiscal third quarter ended August 2026. The consensus earnings estimate was $1.29 per share on revenue of $8.33 billion. The Earnings Whisper number was $1.28 per share. The company missed expectations by 3.91% while revenue fell 8.67% compared to the same quarter a year ago.
The company said it expects fourth-quarter homebuilding revenue of $8.14 billion to $8.74 billion. The current consensus revenue estimate is $9.38 billion for the quarter ending November 30, 2026.
Stuart Miller, Executive Chairman, Chief Executive Officer and President of Lennar, said, "Our third quarter 2026 results reflect consistent focus on our operating strategy of maintaining volume and production while navigating a challenging economic environment. While our earnings of $1.19 per share were below expectations, they reflect the nature of the environment in which we are operating, which has deteriorated since our last earnings call."
Lennar Corporation is one of the nation's leading builders of quality homes for all generations. Lennar builds affordable, move-up and active adult homes primarily under the Lennar brand name.
LuxExperience B.V. (LUXE) reported a loss of $0.04 per share on revenue of $771.70 million for the fiscal fourth quarter ended June 2026. The consensus estimate was a loss of $0.11 per share on revenue of $727.39 million. The Earnings Whisper number was a loss of $0.14 per share. The company beat expectations by 71.43% while revenue grew 15.71% on a year-over-year basis.
The company said it expects fiscal 2027 revenue of $2.989 billion to $3.147 billion. The current consensus revenue estimate is $3.00 billion for the year ending June 30, 2027.
LuxExperience is the leading digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts worldwide.
HIPO
0.0% since the report
0.4% above its post-earnings high
Trusted Earnings Research Since 1998
For more than 25 years, investors and financial professionals have used
Earnings Whispers to look beyond consensus estimates and better understand
the expectations driving stock prices around earnings.
